Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Key Inclusion Criteria:

• Have histologically or cytologically confirmed diagnosis of Stage IIIB or IIIC (whoare not amenable to curative surgery or radiotherapy) or Stage IV NSCLC per theUnion Internationale contre le Cancer/American Joint Committee on Cancer stagingsystem, 8th edition without actionable EGFR mutation or anaplastic lymphoma kinaserearrangement.

• Have at least one measurable lesion as the targeted lesion based on RECIST v1.1.Lesions treated after prior local treatment (radiotherapy, ablation, interventionalprocedures, etc.) are generally not considered as target lesions. If the lesion withprior local treatment is the only targeted lesion, evidence-based radiology must beprovided to demonstrate disease progression (the single bone metastasis or thesingle central nervous system metastasis should not be considered as a measurablelesion).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate organ function.

Key Exclusion Criteria:

• Have histologically or cytologically confirmed NSCLC with small-cell lung cancerhistologic component.

• Have received any of the following therapies or drugs within the noted timeintervals prior to study treatment:

• Participants who received prior treatment with anti-VEGF monoclonal antibody,or PD(L)-1/VEGF bispecific antibody or received platinum-based chemotherapyand/or anti-PD(L)-1 as part of adjuvant or neoadjuvant treatment

• Have received systemic corticosteroids (at a dosage greater than 10 mg/day ofprednisone or an equivalent dose of other corticosteroids) within 14 days priorto the initiation of study treatment. Note: local, intranasal, intraocular,intra-articular or inhaled corticosteroids, short-term use (≤7 days) ofcorticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) ortreatment of non-autoimmune conditions (e.g., delayed hypersensitivityreactions caused by exposure to allergens) are allowed.

• Have uncontrolled hypertension or poorly controlled diabetic conditions prior tostudy treatment.

• Have a serious non-healing wound, ulcer, or bone fracture. This includes history (within 6 months prior to study entry) or risk of abdominal fistula,tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess.In addition, the participant must have undergone correction (or spontaneous healing)of the perforation/fistula and/or the underlying process causingfistula/perforation.

• Participants with evidence of major coagulation disorders or other significant risksof hemorrhage.

• Have superior vena cava syndrome or symptoms of spinal cord compression.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.